Layoff Tracker: Rome Trims Already-Small Team Amid Strategic Review 2024 was a tough year for the biopharma industry, with several companies including Bayer, Bristol Myers Squibb and Johnson & Johnson cutting hundreds or even thousands of employees. BioSpace will continue to be…
Employee-led initiative supports global partnerships to build stronger, climate-resilient health systems Takeda (TSE:4502/NYSE:TAK) today committed JPY 4.6 billion (approx. USD 32.1 million) to four new Global Corporate Social Responsibility (CSR) partners as part of the company’s ongoing commitment to building…
Silent global health crisis threatens lives, driving heart disease, stroke, and kidney failure worldwide The World Health Organization (WHO) today released its second Global hypertension report, showing that 1.4 billion people lived with hypertension in 2024, yet just over one in…
WuXi Biologics Selected as Constituent of FTSE4Good Index Series for Fifth Consecutive Year WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been selected as a constituent company of the FTSE4Good Index…
First Parkinson’s disease patient treated in BlueRock’s pivotal Phase III trial of investigational cell therapy bemdaneprocel BlueRock Therapeutics LP, a clinical-stage cell therapy company and wholly owned, independently operated subsidiary of Bayer AG, today announced that the first patient has…
Pharma Giant Expands Into Emerging Psychedelic Therapies With AbbVie’s $1.2 billion acquisition of Gilgamesh Pharmaceuticals’ lead depression drug, the psychedelic therapeutics space has soundly rebounded from Lykos’ rejection last year. There are now seven programs in Phase III trials across…
Critics Warn Plan May Hinder Innovation and Patient Access The FDA’s proposed Rare Disease Evidence Principles review process is a starting point for getting rare disease therapies across the finish line, but industry leaders say there are more concrete steps…
The fight against misinformation goes to the heart of trust in public health We are at a critical juncture. While best estimates conclude that vaccines have saved more than 150 million lives in the past 50 years, the potential for…
Nuvation Bio’s IBTROZI™ Wins Regulatory Approval in Japan for Advanced ROS1-Positive Non-Small Cell Lung Cancer Nuvation Bio Inc. (NYSE: NUVB), a global oncology company dedicated to developing novel therapies for some of the most challenging cancers, announced that Japan’s Ministry…
Layoffs From Just 6 Pharmas Could Wipe Out Over 39,000 Jobs This year, Novo Nordisk and Merck announced significant layoffs, with Novo planning to axe about 9,000 employees and Merck projecting it could let go of roughly 6,000. Meanwhile, Bayer,…
Lexicon Backs Phase III Go Decision for Non-Opioid Pain Med With Post-Hoc AnalysisSupporting Lexicon Pharmaceuticals’ decision to advance the non-opioid analgesic pilavapadin into late-stage development—despite a topline miss in March—is an “improving” regulatory environment for non-addictive options for chronic pain,…
Key challenges in AAD sourcing: GMP compliance, supply reliability & quality control Amino acid derivatives (AADs) are essential starting materials for solid-phase peptide synthesis, crucial for the development of peptide-based therapeutics in areas like oncology, metabolic disorders, and infectious diseases. As…
